Skip to main content
. 2023 Apr 17;13:1141500. doi: 10.3389/fonc.2023.1141500

Figure 1.

Figure 1

PFS according to prognostic factors. PFS according to: (A) Gender; (B) Age; (C) Baseline BMI; (D) Performance status (PS); (E) Ki-67 (%); (F) Metastatic Sites; (G) Metastatic disease at diagnosis; (H) Best Response to avelumab; (I) Baseline PLT count; (J) Baseline NLR. BMI, Body Mass Index; NLR, Neutrophil-to-Lymphocyte Ratio; PLT, Platelets; PFS, Progression-free Survival.